Patents by Inventor Tobias Welt

Tobias Welt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human Anti-SOD1 Antibodies
    Publication number: 20240254256
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 15, 2024
    Publication date: August 1, 2024
    Applicants: Neurimmune Holding AG, University of Zurich
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier
  • NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE
    Publication number: 20230287106
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Application
    Filed: November 9, 2022
    Publication date: September 14, 2023
    Applicants: Neurimmune Holding AG, University of Zurich
    Inventors: Jan GRIMM, Fabrice HEITZ, Fabian WIRTH, Tobias WELT
  • Human Anti-SOD1 Antibodies
    Publication number: 20220267471
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
  • Human anti-SOD1 antibodies
    Patent number: 11352441
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: June 7, 2022
    Assignees: NEURIMMUNE HOLDING AG, UNIVERSITY OF ZURICH
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
  • NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE
    Publication number: 20200231667
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance winch are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Application
    Filed: December 5, 2019
    Publication date: July 23, 2020
    Inventors: Jan GRIMM, Fabrice HEITZ, Fabian WIRTH, Tobias WELT
  • Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance
    Patent number: 10544213
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 28, 2020
    Assignees: Neurimmune Holding AG, University of Zurich
    Inventors: Jan Grimm, Fabrice Heitz, Fabian Wirth, Tobias Welt
  • Human Anti-SOD1 Antibodies
    Publication number: 20190284302
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: May 28, 2019
    Publication date: September 19, 2019
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
  • Human anti-SOD1 antibodies
    Patent number: 10344097
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: July 9, 2019
    Assignees: NEURIMMUNE HOLDING AG, UNIVERSITY OF ZURICH
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
  • NOVEL COMPOUNDS CAPABLE OF ANTAGONIZING ISLET AMYLOID POLYPEPTIDE (IAPP) INDUCED BETA-CELL DAMAGE AND IMPAIRED GLUCOSE TOLERANCE
    Publication number: 20180179276
    Abstract: Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced ?-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).
    Type: Application
    Filed: March 12, 2015
    Publication date: June 28, 2018
    Inventors: Jan GRIMM, Fabrice HEITZ, Fabian WIRTH, Tobias WELT
  • Human Anti-SOD1 Antibodies
    Publication number: 20160168267
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 3, 2016
    Publication date: June 16, 2016
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan Mcafoose, Marcel Maier
  • HUMAN ANTI-SOD1 ANTIBODIES
    Publication number: 20140301945
    Abstract: Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 9, 2014
    Applicants: UNIVERSITY OF ZURICH, NEURIMMUNE HOLDING AG
    Inventors: Fabio Montrasio, Maria Grazia Barenco Montrasio, Jan Grimm, Roger Nitsch, Christoph Hock, Tobias Welt, Jordan McAfoose, Marcel Maier